Education and Training
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone
Stanford is currently not accepting patients for this trial.
Intervention(s):
- drug: MM-111
- drug: Paclitaxel
- drug: Trastuzumab
Eligibility
Inclusion Criteria:
- Patients must have documentation of histologically or cytologically confirmed
metastatic or locally advanced adenocarcinoma of the distal esophagus, GE junction or
stomach
- Patients must have documentation of histologically or cytologically confirmed HER2
expression
- Patients must be ≥18 years of age
- Patients must have ECOG PS of 0, 1, or 2
- Patients must have adequate hematologic status, renal and hepatic function
Exclusion Criteria:
- Patients with known hypersensitivity to any of the components of MM-111
- Patients with a known history of hypersensitivity to paclitaxel or other drugs
formulated in Cremophor® EL
- Patients with a known history of hypersensitivity to trastuzumab or any of its
components (group 1 patients only)
- Patients with an active infection or with an unexplained fever >38.5°C
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting